Patents by Inventor Michelle Therese Ma

Michelle Therese Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
    Patent number: 11905301
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: February 20, 2024
    Assignee: Clarity Pharmaceuticals Ltd.
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS
    Publication number: 20210363161
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: August 4, 2021
    Publication date: November 25, 2021
    Inventors: Paul Stephen DONNELLY, Michelle Therese MA, Denis Bernard SCANLON
  • Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
    Patent number: 11111254
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: September 7, 2021
    Assignee: The University of Melbourne
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
    Patent number: 10870664
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: December 22, 2020
    Assignee: The University of Melbourne
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS
    Publication number: 20200115391
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Inventors: Paul Stephen DONNELLY, Michelle Therese MA, Denis Bernard SCANLON
  • Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
    Patent number: 10544164
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: January 28, 2020
    Assignee: The University of Melbourne
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS
    Publication number: 20190225625
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: April 9, 2019
    Publication date: July 25, 2019
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
    Patent number: 10301326
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilizing the radiolabelled compounds of the invention.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 28, 2019
    Assignee: THE UNIVERSITY OF MELBOURNE
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS
    Publication number: 20170267698
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 21, 2017
    Inventors: Paul Stephen DONNELLY, Michelle Therese Ma, Denis Bernard Scanlon
  • NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS
    Publication number: 20170267699
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 21, 2017
    Inventors: Paul Stephen DONNELLY, Michelle Therese MA, Denis Bernard SCANLON
  • Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
    Patent number: 9701694
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: July 11, 2017
    Assignee: THE UNIVERSITY OF MELBOURNE
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon
  • Nitrogen-Containing Macrocyclic Conjugates As Radiopharmaceuticals
    Publication number: 20110293517
    Abstract: The present invention relates to compounds that are useful as metal ligands and which either contain a molecular recognition moiety or can be bound to a molecular recognition moiety and methods of making these compounds. Once the compounds that contain a molecular recognition moiety are coordinated with a suitable metallic radionuclide, the coordinated compounds are useful as radiopharmaceuticals in the areas of radiotherapy and diagnostic imaging. The invention therefore also relates to methods of diagnosis and therapy utilising the radiolabelled compounds of the invention.
    Type: Application
    Filed: December 2, 2009
    Publication date: December 1, 2011
    Applicant: THE UNIVERSITY OF MELBOURNE
    Inventors: Paul Stephen Donnelly, Michelle Therese Ma, Denis Bernard Scanlon